ME - 23andMe Inc Projected Sales Volume

Graphic logo of 23andMe Holding Co (ME)

The stability of 23andMe Holding Co. (ME) is driven by the robotization of genetic testing, a trend confirmed by the company's sales volume on GURU.Markets, where the 0.21 level serves as a critical benchmark. The financial foundation relies on subscriptions and the sale of tests during a business model transition. Simultaneously, the brand is overcoming a crisis of confidence by reshaping its image into a full-fledged clinic for data protection.

Company Future Sales Volume: 23andMe Inc (ME) for 07/04/2022 - 04/05/2025

Financial and market metric breakdowns for 23andMe Inc. (ME)

- stock value and consensus price forecast:
Fundamental valuation:ME 23andMe Inc
Product sample of 23andMe Holding Co

Investors are assessing the business resilience of 23andMe Holding Co. (ME) through the stability of its cash flows. The indicator calculates a daily revenue forecast, filtering out random market volatility to identify real growth potential. By analyzing the trajectory of the company's future sales, one can determine whether there is a margin of safety or a stagnation of drivers. This is critical for 23andMe Holding Co. (ME), as demand for genetic tests is declining. A decrease in this metric confirms the inefficiency of the subscription model and the risk of capital depletion.

Competitors of 23andMe Holding Co. (ME)

Company Projected Revenue Agilent (A)|Projected Sales Volume Quest Diagnostics Incorporated (DGX)|Company Projected Revenue Illumina Corp ILMN|EXAS: Company Revenue Forecast|RVTY: Company Future Sales Volume|Company Sales Forecast bio-rad.com (BIO)|NNNN: Projected Sales Volume|Sotera Health - Company Future Revenue|QDEL (quidel.com) - Projected Sales Volume|OPK: Company Future Revenue|Company Future Sales Volume CDNA (CareDx)|Projected Sales Volume Maravai LifeSciences (MRVI)|Fulgent Genetics, Inc. - Company Future Sales Volume|LAB: Company Revenue Forecast|Cytek Corp - Projected Sales Volume|Company Future Revenue OSUR (OraSure Technologies)|XGN: Projected Sales Volume|MDxHealth - Company Future Revenue|LUCD (luciddx.com) - Projected Sales Volume|PRE - Company Sales Forecast|Company Projected Revenue Insight Molecular Diagnostics Inc (IMDX)|TRIB - Company Expected Sales Volume|Projected Sales Volume PRPH (ProPhase Labs, Inc.)|Company Future Sales ainos.com (AIMD)|Co-Diagnostics Inc - Projected Sales Volume|HSCS - Projected Sales Volume|BMRA (Biomerica Inc) - Company Future Sales Volume|CDIO - Company Future Sales|Company Projected Revenue Onconetix Inc|VRAX - Company Sales Forecast|Company Future Sales Volume BJDX (Bluejay Diagnostics)|Projected Sales Volume Aspira Women's Health, Inc. (AWH)|Company Projected Revenue acceleratediagnostics.com AXDX|Company Projected Revenue Volume CNTG (centogene.com)|ENZ - Company Projected Revenue|FRES - Projected Sales Volume|GENE: Projected Sales Volume|Company Revenue Forecast PMD